Drugs / rESP
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03950687 | Jun 2019 → Jun 2020 | chronic renal failure syndrome | Shenyang Sunshine Pharmaceutical Co., LTD. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rESP | “rESP is a high glucose medium and long-acting recombinant protein products, containing 165 amino acids by adding 3 glycosylation sites” NCT03950687 ↗ |
| Modality | Protein / enzyme biologic | “rESP is a high glucose medium and long-acting recombinant protein products, containing 165 amino acids by adding 3 glycosylation sites” NCT03950687 ↗ |
| Route | Intravenous | “intravenous administration, 0.5μg/kg, once a week, for 32 weeks” NCT03950687 ↗ |